Strategy Asset Managers’s Moderna MRNA Stock Holding History

Strategy Asset Managers’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.51M	Buy	+13,021	New	+$1.4M	0.39%	56

Other funds holding MRNA

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

BVL

Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

LAI

Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return

PFM

Patton Fund Management Dallas, Texas $389M AUM 65.14% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

GCA

Gallagher Capital Advisors Argyle, Texas $187M AUM 21.63% 1-Year Est. Return

NIM

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

BSCCG

Blue Sky Capital Consultants Group Poway, California $239M AUM 14.34% 1-Year Est. Return

Strategy Asset Managers's MRNA Position: Q3 2026 in Review

Strategy Asset Managers opened a new position in Moderna (MRNA) in Q3 2026: 13,021 shares worth $2.51M. The stake represents 0.39% of the portfolio and ranks #56 among its holdings.

92 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Strategy Asset Managers held 13,021 shares of Moderna worth $2.51M as of Q3 2026.
Moderna was a new Strategy Asset Managers position in Q3 2026.
Moderna made up 0.39% of Strategy Asset Managers's portfolio in Q3 2026, its #56 holding.
92 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Strategy Asset Managers's 13F filing for Q3 2026, filed 14 Oct 2026.